Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Consequence of Antivirals Versus Standard Care on Clinical Situation in Patients With COVID-19

Alsaraj et al., Infectious Diseases in Clinical Practice, doi:10.1097/IPC.0000000000001336
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -87% Improvement Relative Risk Favipiravir  Alsaraj et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 104 patients in Iraq (September 2021 - February 2022) Higher mortality with favipiravir (not stat. sig., p=0.26) c19early.org Alsaraj et al., Infectious Diseases in.., Jan 2024 Favorsfavipiravir Favorscontrol 0 0.5 1 1.5 2+
RCT 156 COVID-19 patients showing higher mortality with favipiravir and remdesivir overall. Favipiravir and remdesivir were more effective when started earlier, however note that Table 10 compares earlier favipiravir/remdesivir+standard care with standard care at any time, which will exaggerate the benefits/harms of earlier/later treatment. The confidence intervals for the Cox results are unusually narrow suggesting a possible error in calculation.
This study is excluded in the after exclusion results of meta analysis: potential data issue.
Study covers remdesivir and favipiravir.
risk of death, 87.1% higher, HR 1.87, p = 0.26, treatment 9 of 51 (17.6%), control 5 of 53 (9.4%), adjusted per study, multivariable, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alsaraj et al., 8 Jan 2024, Randomized Controlled Trial, Iraq, peer-reviewed, 6 authors, study period September 2021 - February 2022. Contact: m.n.abed@uomosul.edu.iq.
This PaperFavipiravirAll
Consequence of Antivirals Versus Standard Care on Clinical Situation in Patients With COVID-19
PhD Marwa N Alsaraj, PhD, † ¶ Mohannad E Qazzaz, PhD, ‡ ¶ Mohammed N Abed, PhD Fawaz A Alassaf, PhD,|| ¶ Mohanad A Alfahad, PhD Mahmood H M Jasim
Favipiravir and remdesivir have recently received more clinical interest for the management of COVID-19. The study aimed to explore the effectiveness of favipiravir or remdesivir on the clinical outcome of SARS-CoV-2 patients in comparison with standard care. All patients were given standard care before being randomized into the following 3 groups: standard care group (standard care only), remdesivir group (remdesivir and standard care), and favipiravir group (group 3, favipiravir and standard care). The primary endpoint of the study was time to recovery or the clinical condition of patients on day 14. A total of 156 patients underwent randomization (53 assigned to standard care group, 51 to favipiravir group, and 52 to remdesivir group). The percentage of death in favipiravir and remdesivir groups was higher than those in the standard care group and likewise the liver enzymes. Studying the time to starting therapy showed that early administration of antivirals resulted in lower percentage of mortality. The ratio of hazard for early favipiravir and remdesivir was lower in comparison with those treated with late administration of the same drugs (hazard ratio, 0.62; 95% confidence interval [CI], 0.62-0.73 vs 3.22; 95% CI, 3.21-3.44, respectively, for favipiravir and 0.11; 95% CI, 0.10-0.12 vs 3.44; 95% CI, 3.43-3.55, respectively, for remdesivir). For favipiravir or remdesivir to have more beneficial effects than standard care alone for SARS-CoV-2 patients, they need to be started as early as possible. However, regular monitoring of liver function is required.
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Dawood, Altobje, Alnori, Compatibility of the ligand binding sites in the spike glycoprotein of COVID-19 with those in the aminopeptidase and the caveolins 1, 2 proteins, Res J Pharm Technol
Dubert, Visseaux, Isernia, Case report study of the first five COVID-19 patients treated with remdesivir in France, Int J Infect Dis
Ejaz, Alsrhani, Zafar, COVID-19 and comorbidities: deleterious impact on infected patients, J Infect Public Health
Elsawah, Elsokary, Abdallah, Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis, Rev Med Virol
Frediansyah, Nainu, Dhama, Remdesivir and its antiviral activity against COVID-19: a systematic review, Clin Epidemiol Glob Health
Hu, Guo, Zhou, Characteristics of SARS-CoV-2 and COVID-19, Nat Rev Microbiol
Joshi, Parkar, Ansari, Role of favipiravir in the treatment of COVID-19, Int J Infect Dis
Maldarelli, Savage, Mazur, Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: case report and management discussion, Open Forum Infect Dis
Malik, Ahmed, Mir, The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges, J Infect Public Health
Mohanty, Satapathy, Naidu, Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)-anatomic pathology perspective on current knowledge, Diagn Pathol
Omolo, Soni, Fasiku, Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus, Eur J Pharmacol
Pardo, Shukla, Chamarthi, The journey of remdesivir: from Ebola to COVID-19, Drugs Context
Qomara, Primanissa, Amalia, Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review, Int J Gen Med
Shannon, Selisko, Le, Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis, Nat Commun
Shiraki, Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther
Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19, JAMA
Tian, Liu, Liang, An update review of emerging small-molecule therapeutic options for COVID-19, Biomed Pharmacother
Williamson, Feldmann, Schwarz, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, Nature
Zampino, Mele, Florio, Liver injury in remdesivir-treated COVID-19 patients, Hepatol Int
{ 'indexed': {'date-parts': [[2024, 3, 19]], 'date-time': '2024-03-19T00:16:16Z', 'timestamp': 1710807376173}, 'reference-count': 20, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '2', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2024, 3]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Favipiravir and remdesivir have recently received more clinical interest ' 'for the management of COVID-19. The study aimed to explore the effectiveness of favipiravir ' 'or remdesivir on the clinical outcome of SARS-CoV-2 patients in comparison with standard ' 'care. All patients were given standard care before being randomized into the following 3 ' 'groups: standard care group (standard care only), remdesivir group (remdesivir and standard ' 'care), and favipiravir group (group 3, favipiravir and standard care). The primary endpoint ' 'of the study was time to recovery or the clinical condition of patients on day 14. A total of ' '156 patients underwent randomization (53 assigned to standard care group, 51 to favipiravir ' 'group, and 52 to remdesivir group). The percentage of death in favipiravir and remdesivir ' 'groups was higher than those in the standard care group and likewise the liver enzymes. ' 'Studying the time to starting therapy showed that early administration of antivirals resulted ' 'in lower percentage of mortality. The ratio of hazard for early favipiravir and remdesivir ' 'was lower in comparison with those treated with late administration of the same drugs (hazard ' 'ratio, 0.62; 95% confidence interval [CI], 0.62–0.73 vs 3.22; 95% CI, 3.21–3.44, ' 'respectively, for favipiravir and 0.11; 95% CI, 0.10–0.12 vs 3.44; 95% CI, 3.43–3.55, ' 'respectively, for remdesivir). For favipiravir or remdesivir to have more beneficial effects ' 'than standard care alone for SARS-CoV-2 patients, they need to be started as early as ' 'possible. However, regular monitoring of liver function is required.</jats:p>', 'DOI': '10.1097/ipc.0000000000001336', 'type': 'journal-article', 'created': {'date-parts': [[2024, 1, 10]], 'date-time': '2024-01-10T13:01:03Z', 'timestamp': 1704891663000}, 'page': '1-5', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Consequence of Antivirals Versus Standard Care on Clinical Situation in Patients With COVID-19', 'prefix': '10.1097', 'volume': '32', 'author': [ { 'given': 'Marwa N.', 'family': 'Alsaraj', 'sequence': 'first', 'affiliation': [{'name': 'Alshifaa Hospital, Nineveh Health Directorate'}]}, {'given': 'Mohannad E.', 'family': 'Qazzaz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammed N.', 'family': 'Abed', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fawaz A.', 'family': 'Alassaf', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohanad A.', 'family': 'Alfahad', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mahmood H.M.', 'family': 'Jasim', 'sequence': 'additional', 'affiliation': []}], 'member': '276', 'published-online': {'date-parts': [[2024, 1, 8]]}, 'reference': [ { 'issue': '1', 'key': 'bib1-20240318', 'doi-asserted-by': 'crossref', 'first-page': '103', 'DOI': '10.1186/s13000-020-01017-8', 'article-title': 'Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and ' 'coronavirus disease 19 (COVID-19)—anatomic pathology perspective on ' 'current knowledge', 'volume': '15', 'year': '2020', 'journal-title': 'Diagn Pathol'}, { 'issue': '9', 'key': 'bib2-20240318', 'first-page': '4760', 'article-title': 'Compatibility of the ligand binding sites in the spike glycoprotein of ' 'COVID-19 with those in the aminopeptidase and the caveolins 1, 2 ' 'proteins', 'volume': '14', 'year': '2021', 'journal-title': 'Res J Pharm Technol'}, { 'issue': '12', 'key': 'bib3-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1833', 'DOI': '10.1016/j.jiph.2020.07.014', 'article-title': 'COVID-19 and comorbidities: deleterious impact on infected patients', 'volume': '13', 'year': '2020', 'journal-title': 'J Infect Public Health'}, { 'issue': '2', 'key': 'bib4-20240318', 'doi-asserted-by': 'crossref', 'first-page': '228', 'DOI': '10.1016/j.jiph.2021.12.014', 'article-title': 'The SARS-CoV-2 mutations versus vaccine effectiveness: new ' 'opportunities to new challenges', 'volume': '15', 'year': '2022', 'journal-title': 'J Infect Public Health'}, { 'issue': '3', 'key': 'bib5-20240318', 'doi-asserted-by': 'crossref', 'first-page': '141', 'DOI': '10.1038/s41579-020-00459-7', 'article-title': 'Characteristics of SARS-CoV-2 and COVID-19', 'volume': '19', 'year': '2021', 'journal-title': 'Nat Rev Microbiol'}, { 'key': 'bib6-20240318', 'doi-asserted-by': 'crossref', 'first-page': '173348', 'DOI': '10.1016/j.ejphar.2020.173348', 'article-title': 'Update on therapeutic approaches and emerging therapies for SARS-CoV-2 ' 'virus', 'volume': '883', 'year': '2020', 'journal-title': 'Eur J Pharmacol'}, { 'key': 'bib7-20240318', 'first-page': '1', 'article-title': 'The journey of remdesivir: from Ebola to COVID-19', 'volume': '9', 'year': '2020', 'journal-title': 'Drugs Context'}, { 'issue': '4', 'key': 'bib8-20240318', 'doi-asserted-by': 'crossref', 'first-page': 'e2187', 'DOI': '10.1002/rmv.2187', 'article-title': 'Efficacy and safety of remdesivir in hospitalized Covid-19 patients: ' 'systematic review and meta-analysis including network meta-analysis', 'volume': '31', 'year': '2021', 'journal-title': 'Rev Med Virol'}, { 'key': 'bib9-20240318', 'doi-asserted-by': 'crossref', 'first-page': '111313', 'DOI': '10.1016/j.biopha.2021.111313', 'article-title': 'An update review of emerging small-molecule therapeutic options for ' 'COVID-19', 'volume': '137', 'year': '2021', 'journal-title': 'Biomed Pharmacother'}, { 'key': 'bib10-20240318', 'doi-asserted-by': 'crossref', 'first-page': '123', 'DOI': '10.1016/j.cegh.2020.07.011', 'article-title': 'Remdesivir and its antiviral activity against COVID-19: a systematic ' 'review', 'volume': '9', 'year': '2021', 'journal-title': 'Clin Epidemiol Glob Health'}, { 'key': 'bib11-20240318', 'doi-asserted-by': 'crossref', 'first-page': '501', 'DOI': '10.1016/j.ijid.2020.10.069', 'article-title': 'Role of favipiravir in the treatment of COVID-19', 'volume': '102', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': 'bib12-20240318', 'doi-asserted-by': 'crossref', 'first-page': '107512', 'DOI': '10.1016/j.pharmthera.2020.107512', 'article-title': 'Favipiravir, an anti-influenza drug against life-threatening RNA virus ' 'infections', 'volume': '209', 'year': '2020', 'journal-title': 'Pharmacol Ther'}, { 'issue': '1', 'key': 'bib13-20240318', 'doi-asserted-by': 'crossref', 'first-page': '4682', 'DOI': '10.1038/s41467-020-18463-z', 'article-title': 'Rapid incorporation of favipiravir by the fast and permissive viral RNA ' 'polymerase complex results in SARS-CoV-2 lethal mutagenesis', 'volume': '11', 'year': '2020', 'journal-title': 'Nat Commun'}, { 'key': 'bib14-20240318', 'doi-asserted-by': 'crossref', 'first-page': '8557', 'DOI': '10.2147/IJGM.S332458', 'article-title': 'Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for ' 'COVID-19 treatment: a systematic review', 'volume': '14', 'year': '2021', 'journal-title': 'Int J Gen Med'}, { 'issue': '19', 'key': 'bib15-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'article-title': 'Remdesivir for the treatment of COVID-19—final report', 'volume': '383', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '11', 'key': 'bib16-20240318', 'doi-asserted-by': 'crossref', 'first-page': '1048', 'DOI': '10.1001/jama.2020.16349', 'article-title': 'Effect of remdesivir vs standard care on clinical status at 11 days in ' 'patients with moderate COVID-19', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '7824', 'key': 'bib17-20240318', 'doi-asserted-by': 'crossref', 'first-page': '273', 'DOI': '10.1038/s41586-020-2423-5', 'article-title': 'Clinical benefit of remdesivir in rhesus macaques infected with ' 'SARS-CoV-2', 'volume': '585', 'year': '2020', 'journal-title': 'Nature'}, { 'key': 'bib18-20240318', 'doi-asserted-by': 'crossref', 'first-page': '290', 'DOI': '10.1016/j.ijid.2020.06.093', 'article-title': 'Case report study of the first five COVID-19 patients treated with ' 'remdesivir in France', 'volume': '98', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'issue': '9', 'key': 'bib19-20240318', 'doi-asserted-by': 'crossref', 'first-page': 'ofaa345', 'DOI': '10.1093/ofid/ofaa345', 'article-title': 'Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: ' 'case report and management discussion', 'volume': '7', 'year': '2020', 'journal-title': 'Open Forum Infect Dis'}, { 'issue': '5', 'key': 'bib20-20240318', 'doi-asserted-by': 'crossref', 'first-page': '881', 'DOI': '10.1007/s12072-020-10077-3', 'article-title': 'Liver injury in remdesivir-treated COVID-19 patients', 'volume': '14', 'year': '2020', 'journal-title': 'Hepatol Int'}], 'container-title': 'Infectious Diseases in Clinical Practice', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001336', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 3, 18]], 'date-time': '2024-03-18T23:01:14Z', 'timestamp': 1710802874000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/IPC.0000000000001336'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 1, 8]]}, 'references-count': 20, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2024]]}}, 'URL': 'http://dx.doi.org/10.1097/IPC.0000000000001336', 'relation': {}, 'ISSN': ['1536-9943', '1056-9103'], 'subject': [], 'container-title-short': 'Infect Dis Clin Pract', 'published': {'date-parts': [[2024, 1, 8]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit